journal article·2021-10

In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy

Xuan Zhang, Yan Zhang, Haiping Zheng, Yufeng He, Honglin Jia, Liyuan Zhang, Chunjie Lin, Shuang Chen, Junfeng Zheng, Qunfang Yang, Tao Liu, Xichun Pan, Haigang Zhang, Chenhui Wang, Lei Ren, Wenjun Shan

Acta Biomaterialia· Volume 134
Publisher page

Abstract

Metastasis is the leading cause of death in cancer patients. Eliciting anti-tumor immune responses against lung metastasis is hindered by the immunosuppressive microenvironment. This study explored a biomimetic nanoformulation, comprising a nanovaccine (OP) that delivers tumor antigens and adjuvants spatially and temporally in a virus-like manner, and a pulmonary surfactant-biomimetic liposome with an immunomodulator, JQ1 (PS-JQ1). The findings of this study showed that intratracheal administration of OP+PS-JQ1 activated lung immune cells without concomitant excess inflammation, enhanced tumor antigen cross-presentation, generated a significantly high antigen-specific CD8+ T cell response, and reshaped the immunocellular composition in B16 melanoma tumor-bearing lung. OP+PS-JQ1 nanoformulation exhibited a striking immunotherapeutic efficacy, induced local and systemic tumor suppression, improved survival of mice, initiated immune memory that prevents recurrence of secondary tumors. This stable and nontoxic nanoformulation provides a simple, flexible, and robust strategy for augmenting anti-tumor immunity for metastatic cancer. STATEMENT OF SIGNIFICANCE: Egg glue proteins are produced by female insects, which can make the eggs firmly attached to the oviposition sites, not affected by wind and rain. However, genes encoding insect egg glue proteins have not yet been reported, and the molecular mechanism underpinning their adhesion is still unknown. Our study makes a significant contribution to the literature as it identifies the sequence, structure, adhesive property, and mechanism of silkworm egg glue protein. Furthermore, it outlines key insights into the structure-function relationships associated with egg glue proteins. We believe that this paper will be of interest to the readership of your journal as it identifies the first complete sequence of insect egg glue proteins, thereby highlighting their potentials future applications in both the biomedical and technical fields.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Invertebrate Immune Response Mechanisms · Immunotherapy and Immune Responses · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (51)

Show source-provided references
1. Cancer immunoprevention10.1016/j.coi.2016.01.002 ↗
2. Treating metastatic cancer with nanotechnology10.1038/nrc3180 ↗
3. The metabolism of cancer cells during metastasis10.1038/s41568-020-00320-2 ↗
4. Strategies for the discovery and development of therapies for metastatic breast cancer, Nature reviews10.1038/nrd2372 ↗
5. Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases10.1038/s41551-020-00644-2 ↗
6. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion10.1126/science.1203486 ↗
7. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy10.1038/nri.2017.49 ↗
8. Understanding the tumor immune microenvironment (TIME) for effective therapy10.1038/s41591-018-0014-x ↗
9. Tumour-associated macrophages as treatment targets in oncology10.1038/nrclinonc.2016.217 ↗
10. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity10.1038/nature22396 ↗
11. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL10.1182/blood-2010-11-321752 ↗
12. Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response
13. Molecular and biochemical aspects of the PD-1 checkpoint pathway10.1056/NEJMra1514296 ↗
14. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma10.1073/pnas.1906346116 ↗
15. Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat3 suppression10.1016/j.freeradbiomed.2019.12.018 ↗
16. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment10.1016/j.jconrel.2016.11.013 ↗
17. Immuno-oncology: emerging targets and combination therapies10.3389/fonc.2018.00315 ↗
18. Modulating the tumor microenvironment to enhance tumor nanomedicine delivery10.3389/fphar.2017.00952 ↗
19. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models10.1172/JCI86437 ↗
20. BET Bromodomain inhibition selectively targets the Epstein-barr virus oncogene LMP1 while promoting Virus-Specific
21. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer10.1021/acsami.9b18730 ↗
22. The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly10.1055/s-0030-1265897 ↗
23. Effects of nanoparticles on the mechanical functioning of the lung10.1016/j.cis.2015.10.002 ↗
24. GSH depletion liposome adjuvant for augmenting the photothermal immunotherapy of breast cancer10.1126/sciadv.abc4373 ↗
25. Hu · 2021
26. Nanoparticles in cancer therapy and diagnosis10.1016/j.addr.2012.09.006 ↗
27. Nanoparticle-based nanomedicines to promote cancer immunotherapy: recent advances and future directions10.1002/smll.201900262 ↗
28. Nano delivery systems and cancer immunotherapy10.1007/s40005-018-0399-z ↗
29. Immunostimulation and Immunosuppression: nanotechnology on the Brink10.1002/smtd.201700347 ↗
30. Virus-like particles in vaccine development10.1586/erv.10.115 ↗
31. Bioengineered Nanocage from HBc protein for combination cancer immunotherapy10.1021/acs.nanolett.8b04722 ↗
32. Arginine-Based Poly(I:C)-Loaded Nanocomplexes for the Polarization of Macrophages Toward M1-Antitumoral Effectors10.3389/fimmu.2020.01412 ↗
33. Modularized peptides modified HBc virus-like particles for encapsulation and tumor-targeted delivery of doxorubicin10.1016/j.nano.2017.12.002 ↗
34. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer10.1038/nnano.2015.292 ↗
35. Metabolic characterization of polarized M1 and M2 bone marrow-derived macrophages using real-time extracellular flux analysis10.3791/53424 ↗
36. Immunotherapeutic effects of intratumoral nanoplexed poly I:C10.1186/s40425-019-0568-2 ↗
37. Vaccination with poly (IC: LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer10.1186/s13045-017-0459-2 ↗
38. Tumor-associated myeloid cells: diversity and therapeutic targeting10.1038/s41423-020-00613-4 ↗
39. CD206+ M2-like macrophages regulate systemic glucose metabolism by inhibiting proliferation of adipocyte progenitors10.1038/s41467-017-00231-1 ↗
40. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity10.1126/science.aau0810 ↗
41. Innate and adaptive immune cells in the tumor microenvironment10.1038/ni.2703 ↗
42. The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis10.1158/2326-6066.CIR-15-0313 ↗
43. Human breast cancer cells educate macrophages toward the M2 activation status10.1186/s13058-015-0621-0 ↗
44. Monocyte-derived dendritic cells: targets as potent antigen-presenting cells for the design of vaccines against infectious diseases10.1016/j.ijid.2013.09.023 ↗
45. How advances in immunology provide insight into improving vaccine efficacy10.1016/j.vaccine.2014.03.078 ↗
46. The immune battlefield: the impact of inflammatory cytokines on CD8(+) T-cell immunity10.1371/journal.ppat.1006618 ↗
47. Antigen-presenting cells: professionals and amateurs10.1016/S0960-9822(95)00219-3 ↗
48. CD4+ T cell help in cancer immunology and immunotherapy10.1038/s41577-018-0044-0 ↗
49. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review10.1002/jcp.27782 ↗
50. Macrophage polarity in cancer: a review10.1002/jcb.27646 ↗
51. Protein Kinase C eta is required for T cell activation and homeostatic proliferation10.1126/scisignal.2002058 ↗